Actively Recruiting
A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis
Led by Almirall, S.A. · Updated on 2025-02-07
1000
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured using validated 5-item World Health Organization Well-being Index (WHO-5) and to investigate effectiveness and safety of lebrikizumab, treatment satisfaction, and long-term effect of lebrikizumab treatment on participants in terms of disease symptomatology/control, fatigue, work impairment, patient's relationship with their skin, and overall QOL among adult participants.
CONDITIONS
Official Title
A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult (greater than or equal to [>=] 18 years) male or female participants with diagnosis of moderate-to-severe Atopic dermatitis.
- Adult participants prescribed lebrikizumab as part of routine/usual care to manage their moderate-to severe Atopic dermatitis.
- Willingness and ability to participate in the study; participants must give their written consent to participate.
You will not qualify if you...
- Hypersensitivity to the active substances or to any of the excipients of lebrikizumab (Ebglyss4).
- Participants with pre-existing helminth infections. These participants should be treated for helminth infection before starting lebrikizumab therapy.
- Concomitant use of live and live attenuated vaccines.
- Pregnant women, except when the potential benefit justifies the potential risk.
- Participants included in a clinical trial at baseline or at any time during the planned study period.
- Participants unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study.
- Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aarhus University Hospital
Aarhus, Denmark, Denmark
Actively Recruiting
Research Team
È
Èric Massana
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here